Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV
Ocular Therapeutix (NASDAQ: OCUL) has announced its participation in two major healthcare events. The company will present at the Jefferies London Healthcare Conference on November 20, 2024, featuring a fireside chat at 9:00 AM GMT, which will be accessible via webcast on the company's investor website.
Additionally, the company will participate in the Ophthalmology Innovation Summit XIV in San Diego on November 22-23, 2024. The event will feature three sessions: a Retina Innovation Showcase presented by Chief Strategy Officer Sanjay Nayak, a Glaucoma Spotlight panel featuring Board Member Adrienne Graves, and 'A View From The Street' panel moderated by CEO Pravin U. Dugel.
Ocular Therapeutix (NASDAQ: OCUL) ha annunciato la sua partecipazione a due importanti eventi nel settore sanitario. L'azienda presenterà al Jefferies London Healthcare Conference il 20 novembre 2024, con una chiacchierata accanto al fuoco alle 9:00 AM GMT, che sarà accessibile tramite webcast sul sito web per investitori dell'azienda.
Inoltre, l'azienda parteciperà all'Ophthalmology Innovation Summit XIV a San Diego il 22-23 novembre 2024. L'evento presenterà tre sessioni: una Vetrina di Innovazione Retinica presentata dal Chief Strategy Officer Sanjay Nayak, un panel Spotlight sul Glaucoma con la presenza della Membro del Consiglio Adrienne Graves, e un panel intitolato 'A View From The Street' moderato dal CEO Pravin U. Dugel.
Ocular Therapeutix (NASDAQ: OCUL) ha anunciado su participación en dos importantes eventos sanitarios. La empresa presentará en la Jefferies London Healthcare Conference el 20 de noviembre de 2024, con una charla junto a la chimenea a las 9:00 AM GMT, que será accesible a través de webcast en el sitio web para inversores de la empresa.
Adicionalmente, la empresa participará en el Ophthalmology Innovation Summit XIV en San Diego el 22-23 de noviembre de 2024. El evento contará con tres sesiones: una Muestra de Innovación Retina presentada por el Director de Estrategia Sanjay Nayak, un panel sobre Glaucoma con la Miembro de la Junta Adrienne Graves, y un panel titulado 'A View From The Street' moderado por el CEO Pravin U. Dugel.
Ocular Therapeutix (NASDAQ: OCUL)는 두 개의 주요 건강 관리 행사에 참여한다고 발표했습니다. 이 회사는 2024년 11월 20일 Jefferies London Healthcare Conference에 발표하며, GMT 기준 오전 9시에 화기애애한 대화(fireside chat)를 진행할 예정이며, 이 내용은 회사의 투자자 웹사이트를 통해 웹캐스트로 접속할 수 있습니다.
추가적으로, 이 회사는 2024년 11월 22-23일 샌디에이고에서 열리는 Ophthalmology Innovation Summit XIV에도 참여할 예정입니다. 이번 행사에서는 세 가지 세션이 마련되어 있으며: 최고 전략 책임자인 Sanjay Nayak가 발표하는 망막 혁신 전시회, 이사회 멤버인 Adrienne Graves가 참여하는 녹내장 주제 패널, 그리고 CEO Pravin U. Dugel이 진행하는 'A View From The Street' 패널이 포함됩니다.
Ocular Therapeutix (NASDAQ: OCUL) a annoncé sa participation à deux grands événements de santé. L'entreprise présentera à la Jefferies London Healthcare Conference le 20 novembre 2024, avec une discussion au coin du feu à 9h00 GMT, accessible par webcast sur le site des investisseurs de l'entreprise.
De plus, l'entreprise participera au Ophthalmology Innovation Summit XIV à San Diego les 22 et 23 novembre 2024. L'événement comprendra trois sessions : une présentation sur l'innovation rétinienne par le directeur de la stratégie Sanjay Nayak, un panel sur le glaucome avec la membre du conseil Adrienne Graves, et un panel intitulé 'A View From The Street' modéré par le PDG Pravin U. Dugel.
Ocular Therapeutix (NASDAQ: OCUL) hat seine Teilnahme an zwei wichtigen Gesundheitsveranstaltungen angekündigt. Das Unternehmen wird am 20. November 2024 auf der Jefferies London Healthcare Conference präsentieren, die um 9:00 Uhr GMT mit einem Fireside-Chat beginnt, der über einen Webcast auf der Unternehmenswebsite für Investoren zugänglich sein wird.
Darüber hinaus nimmt das Unternehmen am Ophthalmology Innovation Summit XIV in San Diego am 22. und 23. November 2024 teil. Die Veranstaltung umfasst drei Sitzungen: eine Retina-Innovationspräsentation, die von Chief Strategy Officer Sanjay Nayak vorgestellt wird, ein Glaukom-Panel mit Vorstandsmitglied Adrienne Graves, sowie ein Panel mit dem Titel 'A View From The Street', das von CEO Pravin U. Dugel moderiert wird.
- None.
- None.
BEDFORD, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced upcoming presentations at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV.
Jefferies London Healthcare Conference 2024
Fireside Chat Date: Wednesday, November 20, 2024
Fireside Chat Time: 9:00 AM GMT
Location: London, UK
A live webcast of the Jefferies fireside chat can be accessed by visiting the Investors section of the Company’s website at investors.ocutx.com.
Ophthalmology Innovation Summit XIV: November 22-23
Location: San Diego, CA
- Session Title: Retina Innovation Showcase
Session Date/Time: Saturday, November 23, 2024, 11:20 AM – 12:55 PM PT
Presenter: Sanjay Nayak, MBBS, PhD, Chief Strategy Officer
- Panel Title: Glaucoma Spotlight: Innovation vs Standard of Care
Panel Date/Time: Saturday, November 23, 2024, 3:20 – 3:50 PM PT
Panelist: Adrienne Graves, PhD, Board Member
- Panel Title: A View From The Street
Panel Date/Time: Saturday, November 23, 2024, 5:00 – 5:30 PM PT
Moderator: Pravin U. Dugel, MD, Executive Chair, President and CEO
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions. AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA™ (travoprost intracameral implant or OTX-TIC), which is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.
Follow the Company on its website, LinkedIn, or X.
The Ocular Therapeutix logo and DEXTENZA® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
FAQ
When is Ocular Therapeutix (OCUL) presenting at the Jefferies London Healthcare Conference 2024?
What sessions will OCUL participate in at the Ophthalmology Innovation Summit XIV?
How can investors access OCUL's Jefferies Conference presentation?
Who will represent OCUL at the Ophthalmology Innovation Summit XIV?
